Unfractionated Heparin Dosing and Monitoring for Acute Pulmonary Embolism

Weight‑Based Dosing Regimen

The British Thoracic Society recommends a weight‑adjusted unfractionated heparin regimen (80 units/kg IV bolus followed by 18 units/kg/hour infusion) for adults with acute PE and normal renal function, because this approach achieves therapeutic anticoagulation more rapidly than fixed‑dose protocols. 1
FDA labeling endorses the same weight‑based dosing (80 units/kg bolus, 18 units/kg/hour) and notes that it is superior to fixed‑dose regimens for achieving target anticoagulation. [2][3]

The British Thoracic Society advises checking the first activated partial thromboplastin time (aPTT) 4–6 hours after the infusion is started. 1
Therapeutic aPTT should be maintained at a ratio of 1.5–2.5 × control (approximately 60–85 seconds absolute), which corresponds to anti‑Factor Xa activity of 0.3–0.7 units/mL. [1][2]3
After any dose adjustment, a repeat aPTT should be obtained 6–10 hours later; once the therapeutic range is achieved, daily aPTT monitoring is sufficient. 1

The American Heart Association provides a validated nomogram for aPTT‑guided infusion adjustments:

aPTT result	Adjustment to infusion rate
< 35 seconds (< 1.2 × control)	Add 4 units/kg/hour
35–45 seconds (1.2–1.5 × control)	Add 2 units/kg/hour
46–70 seconds (1.5–2.3 × control)	No change
71–90 seconds (2.3–3 × control)	Decrease 2 units/kg/hour
> 90 seconds (> 3 × control)	Hold infusion 1 hour, then decrease 3 units/kg/hour

After each adjustment, the aPTT should be rechecked 6 hours later to confirm the new level. 3

The British Thoracic Society recommends continuing unfractionated heparin for a minimum of 5 days and until the international normalized ratio (INR) is ≥ 2.0 on two consecutive days before stopping heparin when transitioning to warfarin. 1
Warfarin may be initiated on day 1 or day 2 of heparin therapy, provided the above INR criteria are met before discontinuation of the infusion. 1

Fixed‑dose heparin protocols delay achievement of therapeutic anticoagulation compared with weight‑based dosing, increasing the risk of early recurrent thromboembolism. 3
Premature discontinuation of heparin before the INR has reached ≥ 2.0 for two consecutive days is associated with a higher likelihood of recurrent pulmonary embolism. 1

Weight‑based regimen: Give an initial bolus of 80 units/kg IV followed by a continuous infusion of 18 units/kg/hour to achieve rapid therapeutic anticoagulation in acute PE. 4, 5
Fixed‑dose alternative: A bolus of 5,000–10,000 units IV with a maintenance infusion of 1,300 units/hour is less effective and delays attainment of therapeutic range. 4, 5

First aPTT check: Perform the initial aPTT measurement 4–6 hours after starting the infusion to detect under‑ or over‑anticoagulation. 4, 5
After dose adjustments: Re‑measure aPTT 6–10 hours after any infusion rate change. 4, 5
Once therapeutic: Continue daily aPTT monitoring while the patient remains on UFH. 4, 5

aPTT ratio: Aim for a 1.5–2.5‑fold increase over control (approximately 45–75 seconds). 4, 5

UFH is recommended for patients with hemodynamically unstable (high‑risk) PE, those who require imminent reperfusion therapy (thrombolysis, embolectomy, or catheter‑directed intervention), and patients with severe renal impairment (creatinine clearance < 30 mL/min). 6
In hemodynamically stable patients, low‑molecular‑weight heparin or fondaparinux are preferred because they carry lower risks of major bleeding and heparin‑induced thrombocytopenia. 6

Duration of UFH overlap: Continue UFH for at least 5 days after initiating warfarin therapy. 4, 5
Discontinuation criteria: Stop UFH only when the INR is ≥ 2.0 on two consecutive measurements. 4, 5
Target INR for warfarin: Maintain an INR of 2.0–3.0 (goal ≈ 2.5). 4, 5

Pre‑thrombolysis: Hold UFH before starting thrombolytic therapy. 4, 5
Post‑thrombolysis: Resume UFH at the maintenance dose of 18 units/kg/hour without giving an additional bolus. 4, 5